Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
StemCell Institute's Other Operating Expense for the
three
months ended in Mar. 2026 was 円406 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was 円1,525 Mil.
StemCell Institute's quarterly Other Operating Expense
declined
from Sep. 2025 (円374 Mil) to Dec. 2025 (円363 Mil) but then
increased
from Dec. 2025 (円363 Mil) to Mar. 2026 (円406 Mil).
StemCell Institute's annual Other Operating Expense
increased
from Mar. 2024 (円1,162 Mil) to Mar. 2025 (円1,274 Mil) and
increased
from Mar. 2025 (円1,274 Mil) to Mar. 2026 (円1,510 Mil).
StemCell Institute Other Operating Expense Related Terms
StemCell Institute Other Operating Expense Historical Data
* Premium members only.
The historical data trend for StemCell Institute's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円1,525 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of 円1,525 Mil mean?
StemCell Institute (TSE:7096) has a Other Operating Expense of 円1,525 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on StemCell Institute and its competitors.
Is StemCell Institute's Other Operating Expense too high?
StemCell Institute's current Other Operating Expense is 円1,525 Mil. Overall, StemCell Institute has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does StemCell Institute's Other Operating Expense compare to VRTX and REGN?
StemCell Institute's Other Operating Expense of 円1,525 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on StemCell Institute and its competitors. StemCell Institute's current Other Operating Expense is 円1,525 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCell Institute stock overvalued right now?
Based on GuruFocus' analysis, StemCell Institute (TSE:7096) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,832.73, compared to a current price of 円768.00 — trading 58.1% below its estimated fair value. The current Other Operating Expense is 円1,525 Mil. StemCell Institute's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For StemCell Institute (TSE:7096), the current Other Operating Expense is 円1,525 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is StemCell Institute (TSE:7096) Overvalued in 2026?
Based on GuruFocus' analysis, StemCell Institute stock appears to be undervalued.
The current stock price of 円768.00 is trading 58.1% below its estimated GF Value™ of 円1,832.73.
GuruFocus considers StemCell Institute to be Possible Value Trap.
Key valuation signals for TSE:7096:
Other Operating Expense: 円1,525 Mil
GF Value™: 円1,832.73 vs. price of 円768.00 (58.1% below fair value)
No single metric tells the full story. See the TSE:7096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
StemCell Institute is engaged in the Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects the mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood. The Company operates in a single segment, the cell bank business sales consist of three components: technical fees, storage fees, and other fees.
69GF Score
Get the complete analysis for TSE:7096
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7096 has been successfully added to your 
